{
    "medicine_id": "f62e028e2c2379acfefe51c4fbeb93031a113a15",
    "platform_id": "DB06219",
    "metadata": {
        "name": "Dalvance 500 mg 25mL Injection powder for solution",
        "composition": "500 mg 25mL Dalbavancin",
        "clinical_particulars": {
            "therapeutic_indications": "Dalbavancin for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections ABSSSI caused by susceptible isolates of the following gram positive microorganisms Staphylococcus aureus including methicillin susceptible and methicillin resistant strains Streptococcus pyogenes Streptococcus agalactiae Streptococcus dysgalactiae Streptococcus anginosus group including Streptococcus anginosus Streptococcus intermedius Streptococcus constellatus and Enterococcus faecalis vancomycin susceptible strains FDA Label F2356 Dalbavancin is not active against gram negative bacteria therefore combination therapy may be clinically indicated if the ABSSSI is polymicrobial and includes a suspected or documented gram negative pathogen F2356 To reduce the development of drug resistant bacteria and maintain the effectiveness of dalbavancin and other antibacterial drugs dalbavancin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria FDA Label F2356 When culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy FDA Label F2356 In the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy FDA Label F2356",
            "contraindications": {
                "disease": "Treatment with antibacterial agents can alter the normal flora of the colon leading to growth of C difficile and commonly occurs in the development of C difficile associated diarrhea FDA Label F2356 Other common side effects include nausea vomiting diarrhea headache rash and pruritis FDA Label F2356 Side effects that occurred in less than 2 of patients during clinical trials include blood and lymphatic system disorders gastrointestinal disorders hepatotoxicity anaphylactoid reactions hepatic enzyme elevation hypoglycaemia dizziness bronchospasm urticaria and vascular disorders FDA Label F2356 There have been no adequate or well controlled studies to conclude that use of dalbavancin is safe during pregnancy or breastfeeding FDA Label F2356",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "The antibacterial activity of dalbavancin appears to best correlate with the ratio of area under the concentration time curve to minimal inhibitory concentration AUC MIC for Staphylococcus aureus based on animal models of infection FDA Label F2356 An exposure response analysis of a single study in patients with complicated skin and skin structure infections supports the two dose regimen for which dalbavancin injection is administered FDA Label F2356 Subsequently the recommended dosage regimen of dalbavancin in patients with normal renal function is 1500 mg administered either as a single dose or 1000 mg followed one week later by 500 mg FDA Label F2356 Dalbavancin should be administered over 30 minutes by intravenous infusion FDA Label F2356 Furthermore inn a randomized positive and placebo controlled thorough QT QTc study 200 healthy subjects received either dalbavancin 1000 mg intravenous IV dalbavancin 1500 mg IV oral moxifloxacin 400 mg or placebo Neither dalbavancin 1000 mg nor dalbavancin 1500 mg had any clinically relevant adverse effect on cardiac repolarization FDA Label F2356",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB12768",
                        "description": "The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dalbavancin"
                    },
                    {
                        "drugbank-id": "DB14022",
                        "description": "The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dalbavancin"
                    },
                    {
                        "drugbank-id": "DB00266",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Dicoumarol"
                    },
                    {
                        "drugbank-id": "DB00498",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Phenindione"
                    },
                    {
                        "drugbank-id": "DB00682",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Warfarin"
                    },
                    {
                        "drugbank-id": "DB00946",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Phenprocoumon"
                    },
                    {
                        "drugbank-id": "DB01418",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Acenocoumarol"
                    },
                    {
                        "drugbank-id": "DB03410",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with 4 hydroxycoumarin"
                    },
                    {
                        "drugbank-id": "DB04665",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Coumarin"
                    },
                    {
                        "drugbank-id": "DB08496",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with R warfarin"
                    },
                    {
                        "drugbank-id": "DB08794",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Ethyl biscoumacetate"
                    },
                    {
                        "drugbank-id": "DB13136",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Fluindione"
                    },
                    {
                        "drugbank-id": "DB13275",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Clorindione"
                    },
                    {
                        "drugbank-id": "DB13347",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Diphenadione"
                    },
                    {
                        "drugbank-id": "DB13451",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with Tioclomarol"
                    },
                    {
                        "drugbank-id": "DB14055",
                        "description": "The risk or severity of bleeding can be increased when Dalbavancin is combined with S Warfarin"
                    },
                    {
                        "drugbank-id": "DB14443",
                        "description": "The therapeutic efficacy of Vibrio cholerae CVD 103 HgR strain live antigen can be decreased when used in combination with Dalbavancin"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}